|From: Sqwii (Rep: 389)||Date: 05/11/2012 03:47|
|Forum: Neurocrine Biosciences - Msg #1077||Thread #673400691 (Rec: 0) |
|NBIX another one I like here at 6.96$ for some news coming near term this month|
Urocortin 2 Update
The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is conducting a Phase II study of urocortin 2 in acute decompensated heart failure patients. This study is now complete and top-line results are expected shortly.
The Company has completed several Phase I studies and two Phase II studies of urocortin 2 in patients with stable congestive heart failure. These Phase II studies showed urocortin 2 to be well tolerated with positive hemodynamic effects as evidenced by increases in cardiac output and efficiency.
Started my own blog www.SqwiiTrader.com
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.